Geoffrey Shouse1, Liana Nikolaenko2. 1. Department of Hematology/Hematopoietic Cell Transplantation, City of Hope National Medical Center, 1500 E Duarte Road, Duarte, CA, 91010, USA. 2. Department of Hematology/Hematopoietic Cell Transplantation, City of Hope National Medical Center, 1500 E Duarte Road, Duarte, CA, 91010, USA. lnikolaenko@coh.org.
Abstract
PURPOSE OF REVIEW: T cell lymphoproliferative disorders represent a diverse group of hematologic malignancies with poor prognosis underscoring the need for novel therapeutic approaches. Disruption of the JAK/STAT signaling pathway has been described in this group of blood cancers and may represent an approach for targeted therapy. Here, we summarize the current data describing the disruptions of JAK/STAT signaling in T cell malignancies and focus on the existing evidence for exploitation of this pathway with targeted therapies. RECENT FINDINGS: To date, preclinical studies have demonstrated the efficacy of JAK/STAT inhibition in the treatment of several T cell lymphoproliferative disorders. More recently, several early clinical trials have demonstrated promising results utilizing this approach as well. The benefit of the combination of JAK/STAT-targeted therapies along with immunotherapy and other molecularly targeted therapies is also discussed. There is substantial evidence that targeting the JAK/STAT pathway in T cell lymphoproliferative disorders could be of clinical benefit. There are several early clinical trials showing promise and many ongoing trials investigating the optimal utility of agents that inhibit this signaling pathway. In addition, targeting this pathway may provide a platform for further rational combination therapies.
PURPOSE OF REVIEW: T cell lymphoproliferative disorders represent a diverse group of hematologic malignancies with poor prognosis underscoring the need for novel therapeutic approaches. Disruption of the JAK/STAT signaling pathway has been described in this group of blood cancers and may represent an approach for targeted therapy. Here, we summarize the current data describing the disruptions of JAK/STAT signaling in T cell malignancies and focus on the existing evidence for exploitation of this pathway with targeted therapies. RECENT FINDINGS: To date, preclinical studies have demonstrated the efficacy of JAK/STAT inhibition in the treatment of several T cell lymphoproliferative disorders. More recently, several early clinical trials have demonstrated promising results utilizing this approach as well. The benefit of the combination of JAK/STAT-targeted therapies along with immunotherapy and other molecularly targeted therapies is also discussed. There is substantial evidence that targeting the JAK/STAT pathway in T cell lymphoproliferative disorders could be of clinical benefit. There are several early clinical trials showing promise and many ongoing trials investigating the optimal utility of agents that inhibit this signaling pathway. In addition, targeting this pathway may provide a platform for further rational combination therapies.
Entities:
Keywords:
AITL; ALCL; CTCL; JAK; NK cell lymphoma; PTCL; STAT; T cell lymphoma; T cell lymphoproliferative disorders; T-ALL
Authors: Meili Zhang; Lesley A Mathews Griner; Wei Ju; Damien Y Duveau; Rajarshi Guha; Michael N Petrus; Bernard Wen; Michiyuki Maeda; Paul Shinn; Marc Ferrer; Kevin D Conlon; Richard N Bamford; John J O'Shea; Craig J Thomas; Thomas A Waldmann Journal: Proc Natl Acad Sci U S A Date: 2015-09-22 Impact factor: 11.205
Authors: Kathryn G Roberts; Ryan D Morin; Jinghui Zhang; Martin Hirst; Yongjun Zhao; Xiaoping Su; Shann-Ching Chen; Debbie Payne-Turner; Michelle L Churchman; Richard C Harvey; Xiang Chen; Corynn Kasap; Chunhua Yan; Jared Becksfort; Richard P Finney; David T Teachey; Shannon L Maude; Kane Tse; Richard Moore; Steven Jones; Karen Mungall; Inanc Birol; Michael N Edmonson; Ying Hu; Kenneth E Buetow; I-Ming Chen; William L Carroll; Lei Wei; Jing Ma; Maria Kleppe; Ross L Levine; Guillermo Garcia-Manero; Eric Larsen; Neil P Shah; Meenakshi Devidas; Gregory Reaman; Malcolm Smith; Steven W Paugh; William E Evans; Stephan A Grupp; Sima Jeha; Ching-Hon Pui; Daniela S Gerhard; James R Downing; Cheryl L Willman; Mignon Loh; Stephen P Hunger; Marco A Marra; Charles G Mullighan Journal: Cancer Cell Date: 2012-08-14 Impact factor: 31.743
Authors: Matthew McKinney; Andrea B Moffitt; Philippe Gaulard; Marion Travert; Laurence De Leval; Alina Nicolae; Mark Raffeld; Elaine S Jaffe; Stefania Pittaluga; Liqiang Xi; Tayla Heavican; Javeed Iqbal; Karim Belhadj; Marie Helene Delfau-Larue; Virginie Fataccioli; Magdalena B Czader; Izidore S Lossos; Jennifer R Chapman-Fredricks; Kristy L Richards; Yuri Fedoriw; Sarah L Ondrejka; Eric D Hsi; Lawrence Low; Dennis Weisenburger; Wing C Chan; Neha Mehta-Shah; Steven Horwitz; Leon Bernal-Mizrachi; Christopher R Flowers; Anne W Beaven; Mayur Parihar; Lucile Baseggio; Marie Parrens; Anne Moreau; Pierre Sujobert; Monika Pilichowska; Andrew M Evens; Amy Chadburn; Rex K H Au-Yeung; Gopesh Srivastava; William W L Choi; John R Goodlad; Igor Aurer; Sandra Basic-Kinda; Randy D Gascoyne; Nicholas S Davis; Guojie Li; Jenny Zhang; Deepthi Rajagopalan; Anupama Reddy; Cassandra Love; Shawn Levy; Yuan Zhuang; Jyotishka Datta; David B Dunson; Sandeep S Davé Journal: Cancer Discov Date: 2017-01-25 Impact factor: 39.397